Antineoplastic effect of doxorubizen in vitro in continuous and primary human anaplastic thyroid cancer cells
Endocrine · 21.11.2024 · 87 (3) · 1050-1059
DOI: 10.1007/s12020-024-04088-5 ↗Kurz gefasst
Fachartikel in der Zeitschrift Endocrine, online erschienen am 21.11.2024. Verfasst von Giusy Elia und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Surgery, Medical and Molecular Pathology and Critical Area, University of Pisa, Pisa, Italy. Hauptthemen laut MEDLINE: Thyroid Carcinoma, Anaplastic, Doxorubicin, Thyroid Neoplasms, Antineoplastic Agents. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 58 Literaturangaben. Gefördert von: Ariel Scientific Innovations (ASI) Ltd., Ariel University, Israel.
Abstract (Originalsprache)
PURPOSE: New drugs are needed for the therapy of anaplastic thyroid cancer (ATC). This study aims to investigate doxorubizen (a dual-action structural hybrid (chimera) of doxorubicin (Dox) and DNA methylating drug temozolomide), in comparison with Dox, and alone or in combination with lenvatinib in ATC 8305C cells, and in primary human ATC cell cultures (pATC). METHODS: We have investigated doxorubizen, Dox, and lenvatinib on 5 different pATC and in continuous 8305C cell line in vitro, evaluating their effect on cells proliferation by WST-1, apoptosis (Hoechst ad Annexin V assays) and migration (Chemicon QCM™ 96-well Migration Assay). RESULTS: The results have demonstrated: (1) a significant antiproliferative and proapoptotic effect of doxorubizen in 8305C and in pATC; (2) a significant antiproliferative and proapoptotic effect of Dox in pATC, and in 8305C; (3) the antineoplastic effect of lenvatinib in 8305C and in pATC; (4) a stronger antiproliferative and proapoptotic effect of doxorubizen than that of Dox, or lenvatinib; (5) that doxorubizen induced an inhibition of migration in pATC stronger than that of Dox, or lenvatinib; (6) that doxorubizen is able to synergize in vitro with lenvatinib increasing the antiproliferative effect, while doxorubizen alone is the primary factor that promotes the proapoptotic impact. CONCLUSION: We have first shown that doxorubizen has a potent antineoplastic effect in vitro in 8305C and in 5 different pATC, and that can synergize with lenvatinib. These results open the way to a future evaluation of the antineoplastic effect of doxorubizen in ATC patients.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Surgery, Medical and Molecular Pathology and Critical Area, University of Pisa, Pisa, Italy.
- Department of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy.
- Department of Chemical Sciences, The Faculty of Natural Sciences, Ariel University, Ariel, Israel.
- Department of Chemical Sciences, The Faculty of Natural Sciences, Ariel University, Ariel, Israel. garyg@ariel.ac.il.
- Department of Translational Research and New Technologies in Medicine and Surgery, University of Pisa, Pisa, Italy. poupak.fallahi@unipi.it.
Förderung
- Ariel Scientific Innovations (ASI) Ltd., Ariel University, Israel
Zitieren
APA
Elia, G., Ferrari, S. M., Tkachenko, I., Walunj, D., Balestri, E., Botrini, C., Ragusa, F., Antonelli, A., Gellerman, G., & Fallahi, P. (2024). Antineoplastic effect of doxorubizen in vitro in continuous and primary human anaplastic thyroid cancer cells. Endocrine, 87(3), 1050-1059. https://doi.org/10.1007/s12020-024-04088-5
Vancouver
Elia G, Ferrari SM, Tkachenko I, Walunj D, Balestri E, Botrini C, et al. Antineoplastic effect of doxorubizen in vitro in continuous and primary human anaplastic thyroid cancer cells. Endocrine. 2024;87(3):1050-1059. doi:10.1007/s12020-024-04088-5
BibTeX
@article{Elia2024,
author = {Elia, Giusy and Ferrari, Silvia Martina and Tkachenko, Iryna and Walunj, Dipak and Balestri, Eugenia and Botrini, Chiara and Ragusa, Francesca and Antonelli, Alessandro and Gellerman, Gary and Fallahi, Poupak},
title = {Antineoplastic effect of doxorubizen in vitro in continuous and primary human anaplastic thyroid cancer cells},
journal = {Endocrine},
year = {2024},
volume = {87},
number = {3},
pages = {1050--1059},
doi = {10.1007/s12020-024-04088-5}
}
EUVIMED